

TATA MOTORS LTD


Result Update	
CMP	532
Target Price	560
Previous Target Price	530
Upside	5%
Change from Previous	

Market Data	
BSE Code	500570
NSE Symbol	TATAMOTORS
52wk Range H/L	599/266
Mkt Capital (Rs Cr)	102,489
Av. Volume	535695
Nifty	8,392

Stock Performance			
	1Month	3 Month	1Year
Absolute	14.2	-4.8	61.6
Rel.to Nifty	9.1	-1.2	46.2

Share Holding Pattern-%			
	3QFY17	2QFY17	1QFY17
Promoter	34.7	33.0	33.0
Public	65.3	67.0	67.0
Others	--	--	--
Total	100.0	100.0	100.0

Company Vs NIFTY



Naveen Kumar Dubey

research.insti@microsec.in

Tata Motors posted a growth of 7% YoY in the net revenue to Rs.65900 crore in 2QFY17. Passenger vehicles volume grew by 23% YoY due to higher sales of Tiago, which has a waiting period of 8 to 12 weeks. Commercial vehicle segment remained sluggish during the quarter due to heavy rain and freight issue and posted 1% growth YoY. Jaguar and Land Rover sales volumes were up by 84% and 15% respectively on account of low priced model launches in both the brands during the quarter. Recently launched F-Pace and Evoque convertible have received well response across regions and XF long wheel base launched in China have also shown strong volumes during the quarter. EBITDA Margin was declined by 110 bps to 9.5% in 2QFY17 due to adverse foreign exchange impact of GBP274 mn.

Result Highlights

Gross Margin improved by 190 bps due to soft commodity prices and favourable product mix.

EBITDA Margin contracted by 90 bps during the quarter due to higher other expenses. Higher advertising & promotion expenses on new and awaiting launches, Forex impact and one time provision of customer quality program led to increase in other expenses.

Company reported net profit of Rs.848 crore in 2QFY17 vs net loss of Rs.1740 crore in the same quarter last year.

Outlook

Going ahead, we expect that the current demonetization issue may hamper the automotive industry for next couple of months. But we are hopeful about the recovery very soon due to strong infrastructure activity and new emission norms in the CV space which will result in pre-buying in 4QFY17. The management has started restructuring of its passenger vehicle segment by increasing its supplier base and increasing operational efficiencies by various cost cutting initiatives. Earlier we recommended the stock at Rs.454 and it has achieved our target for Rs.530, but considering the better traction from JLR, improvement in M&HCV segment in domestic market and restructuring of Passenger vehicle business operations we still hold positive view on this stock. At current FY18E P/B of 1.5 the valuation has got little stretched so we recommend to BUY on dips for a target price of Rs.560.

	Rs. In crore				
Financials	2QFY17	1QFY17	2QFY16	QoQ	YoY
Sales	65900	65895	61524	0%	7%
EBITDA	6283	7613	6519	-17%	-4%
Net Profit	848	2260	-1740	-62%	-149%
EBITDA%	9.5%	11.6%	10.6%		
PAT %	1.3%	3.4%	-2.8%		

Investment Arguments

- ♦ **Strong Product Pipeline-** Tata Motors have strong pipeline of new launches going ahead. New launches in India business include Nexon and Hexa SUVs in FY17. On the JLR side New Land Rover Discovery is expected to launch in the 4QFY17, mid-size Range Rover is expected to launch in 2QFY18 and Range Rover Sport expected launch in 4QFY18. These launches will make Land Rover portfolio even stronger. JLR contributes 80% of the total revenue.
- ♦ **Restructuring of Passenger Vehicle segment-** The management has started restructuring its passenger vehicle segment. Earlier, not having a robust supplier base has cost the company in terms of production losses when parts did not reach factories on time or did not arrive at all. So the company is now working on making its supplier base strong. The management is also working on various cost cutting initiatives to improve operational efficiency of India Business.
- ♦ **Increasing Infrastructure activity and BS-IV norms to drive volumes-** Being the largest CV player in the country, Tata Motors is all set to take advantage of the new emission norms. Indian Automobile sector is upgrading itself to BS-IV from 1st April 2017, which will be further upgraded to BS-VI by 2020. So we assume pre-buying to happen in the 4QFY17.
- ♦ **Exports and Defence future growth drivers -** Export growth in FY17 is expected to be in the range of 20-25 percent and over the next couple of years the management aims to take the export contribution to the total CV revenue to about 25%. Company continues to have a good pipeline of defence orders both which have been received as well as expected.
- ♦ **Expanding presence in China-** China looks a sweet spot for JLR in SUV space. The company has started production of Land Rover and Range Rover models there through Cherry JV. Sales volume have also improved from 2700 units in November 2015 to 6000 units in November 2016. Manufacturing these models in China may result in low cost of production for company.

Management Highlights

- ♦ M&HCV segment volume growth in single digit for full year.
- ♦ Buses and LCV segment will continue their positive growth trend for the rest of the year.
- ♦ Exports growth in the range of 20-25%
- ♦ Export contribution to the total CV revenue to about 25% in next couple of years.
- ♦ Company continues to have a good pipeline of defence orders both which have been received as well as expected.
- ♦ The management aims to capture more than 60% market share in next 2 years in 15 tons and above.
- ♦ China joint venture was profitable in the quarter, declared its first dividend, which will mostly be reinvested back into the joint venture.
- ♦ The all-new XF Long wheel base that has been launched in the China market. Production has started and we look forward to ramping up over the next couple of quarters.
- ♦ 50% of raw material cost is Euro denominated. Depreciation in GBP will have negative impact.
- ♦ Production of XE has shifted to castle bromwich from Solihull and this will free up more capacity at Solihull to produce F-Pace. XE, XF and F-Pace share the same platform.
- ♦ The new discovery would be launched in 4QFY17.
- ♦ Capex less than GBP 3.75 billion.
- ♦ Rs.3500 to 4000 crore for research and new product development in FY17 for India business.
- ♦ The company will be increasing prices of its passenger vehicles starting from Rs.5000 upto Rs. 25000, depending on the model, effective from January 1,2017.

Key Risks

- ♦ 80% revenue of the company comes from exports and any adverse movement in currency may impact margins directly.
- ♦ 50% of raw material is Euro denominated and depreciation of GBP may have negative impact.

Financials Snap Shot

INCOME STATEMENT

	FY14	FY15	FY16	FY17E
Revenue (Net of Excise D	232,834	262,796	275,561	283,390
Other Income	829	899	982	1,107
Total Revenue	233,662	263,695	276,543	284,497
COGS	143,586	159,920	162,419	166,620
GPM	38%	39%	41%	41%
Other Expenses	43,826	50,618	60,425	68,337
EBITDA	34,838	39,239	36,756	32,818
EBITDA Margin (%)	15%	15%	13%	12%
Depreciation	11,078	13,389	17,014	20,668
EBIT	23,760	25,850	19,742	12,150
Interest	4,734	4,861	4,623	4,215
PBT	19,854	21,887	16,100	9,041
Tax	4,765	7,643	2,873	2,343
Tax Rate (%)	24%	35%	18%	26%
Reported PAT	13,991	13,986	11,024	8,449
Dividend Paid	640	-	169	129
No. of Shares	274	274	289	289

RATIOS

	FY14	FY15	FY16	FY17E
EPS	51	51	38	29
Book Value	240	206	280	309
DPS	2.3	-	0.6	0.4
Payout (incl. Div. Tax.)	5%	0%	2%	2%
Valuation(x)				
P/E	7.8	9.3	8.7	15.5
Price / Book Value	1.7	2.3	1.2	1.5
Dividend Yield (%)	0.59%	0.00%	0.18%	0.10%
Profitability Ratios				
RoE	21%	25%	14%	9%
RoCE	21%	23%	15%	9%
Turnover Ratios				
Asset Turnover (x)	1.1	1.1	1.0	1.0
Debtors (No. of Days)	16.6	17.5	17.2	17.2
Inventory (No. of Days)	69.3	66.8	75.1	75.1
Creditors (No. of Days)	89.9	79.7	84.3	84.3
Net Debt/Equity (x)	0.7	1.0	0.6	0.6

BALANCE SHEET

	FY14	FY15	FY16	FY17E
Share Capital	644	644	679	679
Reserves	64,960	55,618	80,103	88,423
Net Worth	65,603	56,262	80,783	89,102
Long term Debt	45,259	56,071	51,876	51,876
Short term Debt	9,696	13,140	11,224	9,919
Deferred Tax	1,572	1,343	3,166	3,166
Total Capital Employed	110,862	112,333	132,659	140,979
Net Fixed Assets	97,375	112,423	128,851	143,157
Capital WIP	10,137	9,330	7,809	7,809
Debtors	10,574	12,579	12,990	13,359
Cash & Bank Balances	29,712	32,116	32,880	29,052
Trade payables	57,316	57,407	63,633	65,441
Total Provisions	20,161	21,171	20,519	20,856
Net Current Assets	13,185	14,626	15,718	9,391
Total Assets	219,998	238,658	269,298	280,107

CASH FLOW STATEMENT

	FY14	FY15	FY16	FY17E
OP/(Loss) before Tax	13,991	13,986	11,024	9,041
Depreciation	11,074	13,386	17,014	20,668
Direct Taxes Paid	4,308	4,194	1,994	2,343
OP before WC changes	34,685	43,049	38,609	35,676
CF from Op. Activity	36,151	35,183	39,167	35,835
	-	-	-	-
Capex	(26,975)	(31,614)	(32,682)	(34,974)
CF from Inv. Activity	(29,893)	(34,519)	(38,611)	(34,014)
Repayment of Long Term	23,321	27,393	10,887	-
Interest Paid	(6,171)	(6,307)	(5,704)	(4,215)
Divd Paid (incl Tax)	(689)	(681)	(86)	(129)
CF from Fin. Activity	(3,883)	5,201	(3,193)	(5,650)
Inc/(Dec) in Cash	2,375	5,865	(2,637)	(3,828)
Add: Opening Balance	12,351	16,628	21,128	32,880
Closing Balance	16,628	21,128	19,350	29,052

DISCLAIMER

This document has been prepared by Microsec Capital Limited (hereinafter referred to as MCL) to provide information about the Company (ies)/ sector(s), if any, covered in the report and may be distributed by it and/or its associates.

This report does not construe to be any investment, legal or taxation advice. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and MCL is not soliciting any action based upon it. This report should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this report, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. Neither MCL, its subsidiaries/ Associates, nor its directors, employees, agents, representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information/research reports/ opinions expressed herein.

While we would endeavour to update the information herein on reasonable basis, MCL and/or its associates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MCL and/or its associates from doing so. MCL/it's associates or employees shall not in any way be responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MCL/it's associates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

MCL and its associates, their directors and employees and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MCL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MCL and/or its affiliates and/or employees may have interests/positions, financial or otherwise of over 1% at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this report.

The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Subject Company may have been a client of MCL or its associates during twelve months preceding the date of distribution of the research report. MCL or its associates may have investment banking and other business relationships with some companies covered by our Research Department. Any or all of the foregoing among other things, may give rise to real or potential conflicts of interest.

MCL and it's associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. MCL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

Microsec Capital Ltd. ("MCL") is SEBI registered Research Analyst under SEBI (Research Analyst) Regulation 2014 having registration Number INH300002407. Besides, MCL is SEBI registered stock broker, Depository Participant, Merchant Banker, Portfolio Management Services, AMFI registered Mutual Fund distributor, Insurance Repository, POP with PFRDA.

The Company issues research reports to clients/prospective clients/others without any additional fees/charge.No material disciplinary action impacting equity research analysis activities has been taken by any statutory/ Regulatory authority against MCL.

Analyst Certification The matter related to the report has been taken from sources believed reliable and the views expressed about the subject or issues in this report accurately reflect the personal views of the analyst/analysts. MCL does not compensate partly or in full, directly or indirectly, related to specific recommendations or views expressed by the research analysts. Disclosure of interest statement of research analyst is as below:

- | | |
|---|-----|
| 1.Analyst's ownership of the stocks mentioned | NIL |
| 2.Served as an officer, director or employee in subject Company | NO |

Offices No: 6 , 5th floor Tower- IIInd,
Stellar IT Park Plot No. C -25 , Sector – 62 ,
Noida – 201309 . Delhi NCR Phone : +91-120-4155509
Email: research.insti@microsec.in, Website: www.microsec.in